Cannabinoid CB2 receptor ligand profiling reveals biased signalling and off-target activity

[1]  G. Gruden,et al.  Role of the endocannabinoid system in diabetes and diabetic complications , 2016, British journal of pharmacology.

[2]  Nala Rogers.  Cannabinoid receptor with an 'identity crisis' gets a second look , 2015, Nature Medicine.

[3]  H. Overkleeft,et al.  A natural substrate-based fluorescence assay for inhibitor screening on diacylglycerol lipase α , 2015, Journal of Lipid Research.

[4]  J. Gertsch,et al.  Correlating FAAH and anandamide cellular uptake inhibition using N-alkylcarbamate inhibitors: from ultrapotent to hyperpotent. , 2014, Biochemical pharmacology.

[5]  K. Mackie,et al.  Programming of neural cells by (endo)cannabinoids: from physiological rules to emerging therapies , 2014, Nature Reviews Neuroscience.

[6]  R. Mechoulam,et al.  Early phytocannabinoid chemistry to endocannabinoids and beyond , 2014, Nature Reviews Neuroscience.

[7]  K. Mackie,et al.  CB2 Cannabinoid Receptors as a Therapeutic Target—What Does the Future Hold? , 2014, Molecular Pharmacology.

[8]  Alexander Hillebrecht,et al.  Calibration of In Vitro Multidrug Resistance Protein 1 Substrate and Inhibition Assays as a Basis to Support the Prediction of Clinically Relevant Interactions In Vivo , 2014, Drug Metabolism and Disposition.

[9]  Arthur Christopoulos,et al.  Quantification of Ligand Bias for Clinically Relevant β2-Adrenergic Receptor Ligands: Implications for Drug Taxonomy , 2014, Molecular Pharmacology.

[10]  J. Gertsch,et al.  Guineensine is a novel inhibitor of endocannabinoid uptake showing cannabimimetic behavioral effects in BALB/c mice. , 2014, Pharmacological research.

[11]  F. Collins,et al.  Policy: NIH plans to enhance reproducibility , 2014, Nature.

[12]  R. McGuire,et al.  Development of an activity-based probe and in silico design reveal highly selective inhibitors for diacylglycerol lipase-α in brain. , 2013, Angewandte Chemie.

[13]  M. Glass,et al.  Real‐time characterization of cannabinoid receptor 1 (CB1) allosteric modulators reveals novel mechanism of action , 2013, British journal of pharmacology.

[14]  Robert M. Jones,et al.  Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists. , 2013, Journal of medicinal chemistry.

[15]  H. Hamana,et al.  Selective CB2 agonists with anti-pruritic activity: discovery of potent and orally available bicyclic 2-pyridones. , 2013, Bioorganic & medicinal chemistry.

[16]  M. Connor,et al.  A Continuous, Fluorescence-based Assay of µ-Opioid Receptor Activation in AtT-20 Cells , 2013, Journal of biomolecular screening.

[17]  Shane M. Wilkinson,et al.  Improved accessibility to the desoxy analogues of Δ9-tetrahydrocannabinol and cannabidiol , 2013 .

[18]  L. Petrocellis,et al.  Why do cannabinoid receptors have more than one endogenous ligand? , 2012, Philosophical Transactions of the Royal Society B: Biological Sciences.

[19]  P. Malherbe,et al.  Functional monoclonal antibody acts as a biased agonist by inducing internalization of metabotropic glutamate receptor 7 , 2012, British journal of pharmacology.

[20]  Christopher E. Keefer,et al.  Mechanistic insights from comparing intrinsic clearance values between human liver microsomes and hepatocytes to guide drug design. , 2012, European journal of medicinal chemistry.

[21]  Udo Albus,et al.  Book Review: Guide for the Care and use of Laboratory Animals , 1998 .

[22]  Melvin E. Andersen,et al.  Organotypic liver culture models: Meeting current challenges in toxicity testing , 2012, Critical reviews in toxicology.

[23]  L. Carbone.  Pain management standards in the eighth edition of the Guide for the Care and Use of Laboratory Animals. , 2012, Journal of the American Association for Laboratory Animal Science : JAALAS.

[24]  D. Centonze,et al.  Effects of palmitoylation of Cys415 in helix 8 of the CB1 cannabinoid receptor on membrane localization and signalling , 2012, British journal of pharmacology.

[25]  M. Glass,et al.  A new cannabinoid CB2 receptor agonist HU‐910 attenuates oxidative stress, inflammation and cell death associated with hepatic ischaemia/reperfusion injury , 2012, British journal of pharmacology.

[26]  Arthur Christopoulos,et al.  A simple method for quantifying functional selectivity and agonist bias. , 2012, ACS chemical neuroscience.

[27]  Arthur Christopoulos,et al.  Signalling bias in new drug discovery: detection, quantification and therapeutic impact , 2012, Nature Reviews Drug Discovery.

[28]  Khusru Asadullah,et al.  What makes a good drug target? , 2011, Drug discovery today.

[29]  T. Ostenfeld,et al.  A Randomized, Controlled Study to Investigate the Analgesic Efficacy of Single Doses of the Cannabinoid Receptor-2 Agonist GW842166, Ibuprofen or Placebo in Patients With Acute Pain Following Third Molar Tooth Extraction , 2011, The Clinical journal of pain.

[30]  S. Boyce,et al.  Discovery and optimization of 1-(4-(pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivatives as a novel class of selective cannabinoid CB2 receptor agonists. , 2011, Journal of medicinal chemistry.

[31]  A. Chaudhary,et al.  Validation of 96-well equilibrium dialysis with non-radiolabeled drug for definitive measurement of protein binding and application to clinical development of highly-bound drugs. , 2011, Journal of Pharmacy and Science.

[32]  D. Henze,et al.  Decahydroquinoline amides as highly selective CB2 agonists: role of selectivity on in vivo efficacy in a rodent model of analgesia. , 2011, Bioorganic & medicinal chemistry letters.

[33]  P Pacher,et al.  Is lipid signaling through cannabinoid 2 receptors part of a protective system? , 2011, Progress in lipid research.

[34]  Douglas G Altman,et al.  Animal Research: Reporting in vivo Experiments—The ARRIVE Guidelines , 2011, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[35]  E. S. Graham,et al.  Cannabinoid Receptor 1 trafficking and the role of the intracellular pool: implications for therapeutics. , 2010, Biochemical pharmacology.

[36]  I. Cuthill,et al.  Animal Research: Reporting In Vivo Experiments: The ARRIVE Guidelines , 2010, British journal of pharmacology.

[37]  D. Selley,et al.  FAAH−/− Mice Display Differential Tolerance, Dependence, and Cannabinoid Receptor Adaptation After Δ9-Tetrahydrocannabinol and Anandamide Administration , 2010, Neuropsychopharmacology.

[38]  S. Dallavalle,et al.  Enol Carbamates as Inhibitors of Fatty Acid Amide Hydrolase (FAAH) Endowed with High Selectivity for FAAH over the Other Targets of the Endocannabinoid System , 2010, ChemMedChem.

[39]  H. Pan,et al.  Cannabinoid-2 receptor limits inflammation, oxidative/nitrosative stress, and cell death in nephropathy. , 2010, Free radical biology & medicine.

[40]  Alexandros Makriyannis,et al.  Latest advances in cannabinoid receptor agonists , 2009, Expert opinion on therapeutic patents.

[41]  C. Holt.  Design, synthesis and evaluation of fluorescent CB2 cannabinoid receptor ligands , 2009 .

[42]  F. Mach,et al.  CB(2) cannabinoid receptor activation is cardioprotective in a mouse model of ischemia/reperfusion. , 2009, Journal of molecular and cellular cardiology.

[43]  A. Hohmann,et al.  Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain , 2008, British journal of pharmacology.

[44]  B. Cravatt,et al.  A Comprehensive Profile of Brain Enzymes that Hydrolyze the Endocannabinoid 2‐Arachidonoylglycerol , 2007, Chemistry & biology.

[45]  Pál Pacher,et al.  Pivotal Advance: Cannabinoid‐2 receptor agonist HU‐308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis , 2007 .

[46]  H. Pan,et al.  Cannabinoid‐2 receptor mediates protection against hepatic ischemia/reperfusion injury , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[47]  P. Lazzari,et al.  Tricyclic pyrazoles. 4. Synthesis and biological evaluation of analogues of the robust and selective CB2 cannabinoid ligand 1-(2',4'-dichlorophenyl)-6-methyl-N-piperidin-1-yl-1,4-dihydroindeno[1,2-c]pyrazole-3-carboxamide. , 2006, Journal of medicinal chemistry.

[48]  P. Pacher,et al.  The Endocannabinoid System as an Emerging Target of Pharmacotherapy , 2006, Pharmacological Reviews.

[49]  J. Sullivan,et al.  In vitro pharmacological characterization of AM1241: a protean agonist at the cannabinoid CB2 receptor? , 2006, British journal of pharmacology.

[50]  G. Koob,et al.  Δ9-tetrahydrocannabinol immunochemical studies : Haptens, monoclonal antibodies, and a convenient synthesis of radiolabeled Δ9-tetrahydrocannabinol , 2005 .

[51]  Liying Li,et al.  Antifibrogenic role of the cannabinoid receptor CB2 in the liver. , 2005, Gastroenterology.

[52]  N. Ueda,et al.  Molecular Characterization of a Phospholipase D Generating Anandamide and Its Congeners* , 2004, Journal of Biological Chemistry.

[53]  J. Traynor,et al.  The [35S]GTPγS binding assay: approaches and applications in pharmacology , 2003 .

[54]  A. Finazzi-Agro’,et al.  The Endocannabinoid System in Human Keratinocytes , 2003, Journal of Biological Chemistry.

[55]  Michael J Banker,et al.  Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding. , 2003, Journal of pharmaceutical sciences.

[56]  I. Muegge.  Selection criteria for drug‐like compounds , 2003, Medicinal research reviews.

[57]  M. Herkenham,et al.  International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors , 2002, Pharmacological Reviews.

[58]  K Gubernator,et al.  Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. , 1998, Journal of medicinal chemistry.

[59]  K. Mackie,et al.  Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. , 1995, Molecular pharmacology.

[60]  S. Munro,et al.  Molecular characterization of a peripheral receptor for cannabinoids , 1993, Nature.

[61]  P. K. Smith,et al.  Measurement of protein using bicinchoninic acid. , 1985, Analytical biochemistry.

[62]  J. Black,et al.  Operational models of pharmacological agonism , 1983, Proceedings of the Royal Society of London. Series B. Biological Sciences.

[63]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[64]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[65]  R. Mechoulam,et al.  Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish , 1964 .

[66]  Thea Mulder-Krieger,et al.  The endocannabinoid 2-arachidonylglycerol is a negative allosteric modulator of the human A3 adenosine receptor. , 2010, Biochemical pharmacology.

[67]  K. Mackie,et al.  Distribution of cannabinoid receptors in the central and peripheral nervous system. , 2005, Handbook of experimental pharmacology.

[68]  G. Koob,et al.  Delta9-tetrahydrocannabinol immunochemical studies: haptens, monoclonal antibodies, and a convenient synthesis of radiolabeled delta9-tetrahydrocannabinol. , 2005, Journal of medicinal chemistry.

[69]  Giovanni Loriga,et al.  Tricyclic pyrazoles. Part 1: synthesis and biological evaluation of novel 1,4-dihydroindeno[1,2-c]pyrazol-based ligands for CB1and CB2 cannabinoid receptors. , 2003, Bioorganic & medicinal chemistry.

[70]  J. Traynor,et al.  The [35S]GTPgammaS binding assay: approaches and applications in pharmacology. , 2003, Life sciences.

[71]  Antonello,et al.  The Endocannabinoid System in Human Keratinocytes. Evidence that Anandamide Inhibits Epidermal Differentiation through CB1 Receptor-Dependent Inhibition of Protein Kinase C, Activating Protein-1 and Transglutaminase* , 2003 .